Ithaca, N.Y. — June 8, 2009 — Rheonix, Inc. today announced the receipt of a $99,928 Small Business Innovation Research Phase I grant from the National Science Foundation (NSF) to develop a rapid test to monitor recreational water for safety. Upon successful completion of the six month Phase I program, Rheonix will be eligible to compete for additional Phase II funding to finalize the prototype test developed during the Phase… Read More »
Ithaca, N.Y. — May 13, 2009 — Rheonix, Inc. today announced the receipt of a $1.67 Million award from the National Institutes of Health (NIH) as the Company and NIH establish a partnership for the development of point-of-care (POC) technologies for underserved and nontraditional health care settings such as rural and urban community public heath-care clinics and temporary medical facilities established in response to natural or human-made disasters.
“This significant financial… Read More »
Ithaca, N.Y. — March 31, 2009 — Rheonix Inc., a privately-held biomedical device company known for its revolutionary, microfluidic, in vitro diagnostic platform, will receive a $100,000 Phase I grant from the National Institutes of Allergy and Infectious Diseases (NIAID) to develop a biosensor for the rapid detection of the causative agent of tuberculosis (TB) in human clinical specimens. The grant will come through NIAID’s Small Business Innovative Research (SBIR)… Read More »
Ithaca, N.Y. — March 17, 2009 — Rheonix Inc., a privately-held biomedical device company known for its revolutionary, microfluidic, in vitro diagnostic platform, announced an additional $120,000 award from the U.S. Environmental Protection Agency (EPA) to further commercialize its biosensor technology for the rapid detection of Cryptosporidium parvum in drinking water.
Cryptosporidium parvum can cause serious illness in infants and the elderly. The largest outbreak of the infection occurred in Milwaukee… Read More »